A5071700451- Immunodeficiency and Autoimmune Disorders
- Health Sciences Research and Education
- Innovations in Medical Education
- Mesenchymal stem cell research
- Pneumocystis jirovecii pneumonia detection and treatment
- Pediatric health and respiratory diseases
- Complement system in diseases
- Hematopoietic Stem Cell Transplantation
- Parvovirus B19 Infection Studies
- Pharmaceutical Practices and Patient Outcomes
- Congenital Anomalies and Fetal Surgery
- Transplantation: Methods and Outcomes
- Renal Diseases and Glomerulopathies
- Renal Transplantation Outcomes and Treatments
Newcastle upon Tyne Hospital
2021-2023
Great North Children's Hospital
2020-2021
Newcastle upon Tyne Hospitals NHS Foundation Trust
2020
Abstract This study aimed to identify a risk profile for development of transplant-associated thrombotic microangiopathy (TA-TMA) in children undergoing hematopoietic stem cell transplantation (HSCT). Between 2013 and 2016, 439 underwent 474 HSCTs at 2 supraregional United Kingdom centers. At median 153 days post-HSCT, TA-TMA occurred among 25 441 evaluable cases (5.6%) with no evidence center variation. Sex, underlying disease, intensity the conditioning, total body irradiation–based use...
Hematopoietic cell transplantation (HCT) has become standard-of-care for an increasing number of inborn errors immunity (IEI). This report is the first to compare transplant outcomes according T-cell-replete (ie, T-replete) HLA-matched grafts using alemtuzumab (n = 117) and T-cell-depleted T-depleted) HLA-mismatched T-cell receptor-αβ (TCRαβ)/CD19 depletion 47) in children with IEI who underwent HCT between 2014 2019. All patients received treosulfan-based conditioning except DNA repair...
Aim Current prescribing in our trust, the absence of a guideline and licensing for prophylactic posaconazole children under 12 years, is based on paper by Boonsathorn et al. 2018 1 The purpose this audit to evaluate extent which monitoring oral prescribed within paediatric inpatient population line with published recommendations. Targets were 100% patients dosed as recommended ; trough concentrations taken 5–10 days after initial administration; if are not range (>0.7 mg/L) was corrective...